A Phase II Study of INCB050465 plus Ruxolitinib in Patients with Myelofibrosis

Full Title

INCB 50465-201: A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis


Myelofibrosis is a disease of the bone marrow. Ruxolitinib is a drug used to treat myelofibrosis that works by inhibiting an abnormal form of a protein called Jak. In this study, researchers are assessing the safety and effectiveness of adding the investigational drug INCB050465 to ruxolitinib treatment in people with myelofibrosis. They will evaluate two different doses of INCB050465 added to ruxolitinib to assess the effectiveness of this combination treatment for reducing spleen size and myelofibrosis symptoms. Both drugs are taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have myelofibrosis and an enlarged, palpable spleen.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Raajit Rampal at 212-639-2194.